Apontis Pharma AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 36.96 million compared to EUR 55.73 million a year ago. Net loss was EUR 11.3 million compared to net income of EUR 2.69 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.28 EUR | -0.48% | +2.73% | +74.32% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+74.32% | 73.63M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- APPH Stock
- News Apontis Pharma AG
- Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023